orserdu
stemline therapeutics b.v. - elacestrant - neoplasie al seno - terapia endocrina - orserdu monotherapy is indicated for the treatment of postmenopausal women, and men, with estrogen receptor (er) positive, her2-negative, locally advanced or metastatic breast cancer with an activating esr1 mutation who have disease progression following at least one line of endocrine therapy including a cdk 4/6 inhibitor.
nolvadex
astrazeneca s.p.a. - tamoxifene - tamoxifene
tamoxifene ratiopharm
ratiopharm gmbh - tamoxifene - tamoxifene
nomafen
lanova farmaceutici s.r.l. - tamoxifene - tamoxifene
sertam
s.f. group s.r.l. - tamoxifene - tamoxifene
tamoxene
s.f. group s.r.l. - tamoxifene - tamoxifene
tamoxifene aurobindo
aurobindo pharma (italia) s.r.l. - tamoxifene - tamoxifene
fulvestrant sandoz
sandoz s.p.a. - fulvestrant - fulvestrant
fulvestrant teva
teva italia s.r.l. - fulvestrant - fulvestrant
fareston
orion corporation - toremifene - neoplasie al seno - terapia endocrina - trattamento ormonale di prima linea del carcinoma mammario metastatico ormone-dipendente nei pazienti in postmenopausa. fareston non è raccomandato per i pazienti con il recettore per gli estrogeni negativi tumori.